Mathematical Modeling of Remdesivir to Treat COVID-19: Can Dosing Be Optimized?
The antiviral remdesivir has been approved by regulatory bodies such as the European Medicines Agency (EMA) and the US Food and Drug administration (FDA) for the treatment of COVID-19. However, its efficacy is debated and toxicity concerns might limit the therapeutic range of this drug. Computationa...
Main Authors: | Jessica M. Conway, Pia Abel zur Wiesch |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/8/1181 |
Similar Items
-
A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2
by: Alexander Simonis, et al.
Published: (2021-01-01) -
Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned
by: Lars Dölken, et al.
Published: (2021-05-01) -
Case report study of the first five COVID-19 patients treated with remdesivir in France
by: Marie Dubert, et al.
Published: (2020-09-01) -
That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
by: Matthew R. Davis, et al.
Published: (2020-07-01) -
Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment
by: Jiashu Xie, et al.
Published: (2021-06-01)